Guideline‑Recommended Direct‑Acting Antiviral Regimens for Chronic Hepatitis C

1. General Recommendation

• All adults with chronic hepatitis C infection should be treated with interferon‑free direct‑acting antiviral (DAA) regimens; pangenotypic combinations such as sofosbuvir/velpatasvir or glecaprevir/pibrentasvir are the preferred first‑line options for the majority of patients. 1

2. First‑Line Pangenotypic Regimens (Applicable to Patients Without Cirrhosis or With Compensated Cirrhosis, Child‑Pugh A)

These pangenotypic regimens achieve sustained virological response (SVR) rates of 95‑100 % across all genotypes and patient populations. 1

3. Population‑Specific Recommendations

3.1 Patients Without Cirrhosis (Treatment‑Naïve)

• Glecaprevir/pibrentasvir for 8 weeks is the shortest effective regimen. 1, 2
• Sofosbuvir/velpatasvir for 12 weeks is an alternative pangenotypic option. 1, 2

3.2 Patients With Compensated Cirrhosis (Child‑Pugh A)

• Glecaprevir/pibrentasvir for 12 weeks. 1, 2
• Sofosbuvir/velpatasvir for 12 weeks. 1, 2
• Ledipasvir/sofosbuvir for 12 weeks (genotypes 1, 4, 5, 6). 2

3.3 Patients With Decompensated Cirrhosis (Child‑Pugh B/C)

• Protease inhibitors must be avoided because of safety concerns. 3
• Sofosbuvir/velpatasvir for 12 weeks plus ribavirin (starting 600 mg daily) is recommended. 4, 2
• Daclatasvir + sofosbuvir for 12 weeks plus low‑dose ribavirin (600 mg) achieved an 83 % SVR in this group. 4, 2
• Clinical trials reported a 5 % mortality from variceal bleeding during treatment of decompensated patients. 4, 2

3.4 Patients With Severe Renal Impairment or End‑Stage Renal Disease (eGFR < 30 mL/min)

• Sofosbuvir‑containing regimens should be avoided when feasible; protease‑inhibitor‑based regimens are preferred. 5

• For genotypes 2 or 3 in dialysis patients, sofosbuvir/velpatasvir or sofosbuvir/daclatasvir may be used with close renal monitoring; treatment must be stopped immediately if renal function deteriorates. 5

3.5 Treatment‑Experienced Patients (Prior DAA Failure)

3.5.1 Failure of NS5A‑Inhibitor‑Containing Regimens (Genotypes 1 or 4)

• Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks plus ribavirin. 6
• Sofosbuvir + ritonavir‑boosted paritaprevir/ombitasvir/dasabuvir (genotype 1) or + ritonavir‑boosted paritaprevir/ombitasvir (genotype 4) for 12‑24 weeks plus ribavirin; a 24‑week duration is advised for genotype 1a and for patients with F3 fibrosis or compensated cirrhosis. 6

3.5.2 Failure of Sofosbuvir‑Based Regimens Without NS5A Inhibitors

• Retreatment with any of the following is appropriate: sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, or sofosbuvir/daclatasvir. 6

3.5.3 Failure of NS5A Inhibitors in Genotypes 2, 3, 5, 6

• Sofosbuvir/velpatasvir for 24 weeks plus ribavirin. 6

3.6 Priority Populations Requiring Immediate Treatment (Irrespective of Fibrosis Stage)

• HIV or HBV co‑infected individuals.
• Patients awaiting or having undergone liver transplantation.
• Individuals with clinically significant extra‑hepatic manifestations (e.g., symptomatic vasculitis, cryoglobulinemia, HCV‑related nephropathy, non‑Hodgkin B‑cell lymphoma).
• Active injection drug users.
• Men who have sex with men engaging in high‑risk sexual practices.
• Women of child‑bearing age who plan pregnancy.
• Hemodialysis patients.
• Incarcerated individuals.
  *These groups should receive prompt therapy to reduce disease progression and transmission risk. 3

4. Genotype‑Specific Recommendations (When Non‑Pangenotypic Options Are Considered)

• Genotype 1b (no cirrhosis, F0‑F2): Grazoprevir/elbasvir for 8 weeks achieved an 88‑97 % SVR. 1
• Genotypes 5 and 6:
  
  • Ledipasvir/sofosbuvir for 12 weeks.
  • Daclatasvir + sofosbuvir for 12 weeks.
  • Glecaprevir/pibrentasvir (8 weeks without cirrhosis, 12 weeks with cirrhosis).
  • Sofosbuvir/velpatasvir for 12 weeks.
    *All the above are supported by the same evidence base. 2

5. Practical Considerations & Safety

• Ribavirin dosing in renal impairment: Initiate at 200 mg/day and monitor hemoglobin frequently; discontinue if hemoglobin falls below 8.5 g/dL. 5
• Avoid protease inhibitors (e.g., grazoprevir, paritaprevir, simeprevir) in decompensated cirrhosis because of the risk of hepatic decompensation. 3
• Sofosbuvir should be avoided in severe renal impairment unless no alternative regimen exists; renal function must be closely monitored. 5
• Do not defer treatment in patients with active substance use; they should be prioritized to prevent onward transmission. 3

6. Resource‑Limited Settings

• Generic sofosbuvir + daclatasvir provides high SVR rates and should be employed according to genotype‑specific guidance when pangenotypic DAAs are unavailable or unaffordable. 1
• If all DAAs are unavailable, peginterferon alfa + weight‑based ribavirin for 24 weeks remains an acceptable option for genotypes 5 and 6, achieving SVR rates of 70‑86 %. 2

Hepatitis C Treatment Eligibility and Management

Patient Selection and Priority

• The European Association for the Study of the Liver recommends that all patients with chronic HCV infection should be offered treatment without delay, regardless of disease stage, as treatment can prevent complications, improve quality of life, and prevent transmission 7, 8
• Patients with significant fibrosis or cirrhosis, including both compensated and decompensated cirrhosis, should be prioritized for immediate treatment 7, 8, 9
• Patients with clinically significant extrahepatic manifestations, such as symptomatic vasculitis associated with HCV-related mixed cryoglobulinaemia, should receive immediate treatment 7, 9, 10
• Patients at risk of rapid disease progression due to comorbidities, such as non-liver solid organ or stem cell transplant recipients, HBV or HIV coinfection, and diabetes, should be prioritized for treatment 7, 8, 9, 10, 11
• Individuals at risk of transmitting HCV, including people who inject drugs, men who have sex with men engaging in high-risk sexual practices, and women of childbearing age who wish to get pregnant, should be prioritized for treatment 7, 9, 12

Special Considerations

• Patients with decompensated cirrhosis and MELD score ≥18-20 who are liver transplant candidates should generally be transplanted first and treated after transplantation 9, 12
• Patients with moderate fibrosis should receive treatment 9, 10, 11
• Patients with minimal or no fibrosis without extrahepatic manifestations are still eligible for treatment, though timing may be individualized based on patient factors 9, 10, 11

Contraindications to Treatment

• Limited life expectancy due to non-liver-related comorbidities is a contraindication to treatment 7, 8, 9, 12
• Decompensated cirrhosis is a contraindication to regimens containing NS3-4A protease inhibitors 7, 12
• Certain drug interactions, particularly with CYP/P-gp-inducing agents, are contraindications to treatment 7, 13

Assessment Before Treatment

• Evaluation of liver disease severity using non-invasive methods, such as liver stiffness measurement and fibrosis biomarker panels, is recommended 7, 14
• Assessment for portal hypertension in cirrhotic patients is recommended 7, 8
• Evaluation of renal function, diabetes status, and obesity is recommended 7, 8

Treatment Outcomes and Follow-up

• Sustained virological response (SVR) is defined as undetectable HCV RNA 12 weeks or 24 weeks after end of therapy 7, 8
• SVR corresponds to definitive cure in the vast majority of cases 7, 8
• In patients with advanced fibrosis or cirrhosis, SVR reduces but does not eliminate the risk of hepatocellular carcinoma, necessitating continued surveillance 7, 8